FDA Drops the Hammer on the Gray Market Peptide Craze: A Deep Dive into the July 2026 Pharmacy Compounding Advisory Committee Meeting

FDA PCAC Hearing July 2026: What's at Stake for Compounded Peptide Access

This article covers the upcoming July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) hearing on peptides nominated for the 5

FDA to discuss easing restrictions on peptides despite safety concerns

Inside the Grey Market Peptide Economy: Regulatory Gaps and Underground Pharmaceutical Infrastructure

This article investigates the parallel pharmaceutical infrastructure built around grey market peptides like BPC-157 and semaglutide. It cont

FDA Scientists Find Insufficient Evidence for Peptides, Undercutting RFK Jr.'s Push for Expanded Access

FDA career scientists have determined there is insufficient evidence to support the safety and efficacy of peptides being considered for pro

FDA Panel on Peptide Drugs Includes Experts with Financial Ties to Unproven Chemical Industry

The FDA has announced participants for an upcoming meeting to reconsider the safety and effectiveness of controversial peptide drugs. The pa

RFK Jr. pushes peptide deregulation; FDA scientists cite lack of safety evidence

Health Secretary Robert F. Kennedy Jr. is pushing to deregulate several peptides, making them more accessible through compounding pharmacies